REPORTS

Let’s Pullulate and Expand Your Business

Peripheral Arterial Disease (PAD) Therapeutics Market - Global Professional Analysis and Forecast to 2026

Feb 15, 2020  |  161 PAGES  |  REPORT CODE: CMM266985
  • REPORT SUMMARY
  • TABLE OF CONTENTS
  • INDUSTRY COVERAGE

The worldwide Peripheral Arterial Disease (PAD) Therapeutics market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 3.9% during the forecast period.

This report presents the market size and development trends by detailing the Peripheral Arterial Disease (PAD) Therapeutics market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Peripheral Arterial Disease (PAD) Therapeutics market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Peripheral Arterial Disease (PAD) Therapeutics industry and will help you to build a panoramic view of the industrial development.

Peripheral Arterial Disease (PAD) Therapeutics Market, By Type:

  • Anti-Platelet Drugs

  • Dual Antiplatelet Therapy Drugs

  • Others

Peripheral Arterial Disease (PAD) Therapeutics Market, By Application:

  • Hospitals

  • Clinics

  • Others

Some of the leading players are as follows:

  • Betagenon AB (Sweden)

  • Proteon Therapeutics, Inc. (US)

  • Bayer HealthCare Pharmaceuticals (Germany)

  • miRagen Therapeutics, Inc. (US)

  • Multi Gene Vascular Systems Ltd (Israel)

  • Sanofi S.A. (France)

  • Merck & Co., Inc. (US)

  • AnGes MG, Inc. (Japan)

  • AstraZeneca Plc. (UK)

  • Symic Bio, Inc. (US)

  • Athersys, Inc. (US)

  • ViroMed Co. Ltd. (Korea)

  • Bristol-Myers Squibb Company (US)

  • TheraVasc Inc. (US)

Geographically, Major regions are analyzed in details are as follows:

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East & Africa

Table of Contents

1 Methodology and Scope

  • 1.1 Market Segmentation & Scope

    • 1.1.1 Technology Type

    • 1.1.2 Product

    • 1.1.3 Application

    • 1.1.4 Regional scope

    • 1.1.5 Estimates and forecast timeline

  • 1.2 Research Methodology

  • 1.3 Information Procurement

    • 1.3.1 Purchased database

    • 1.3.2 Internal database

    • 1.3.3 Secondary sources

    • 1.3.4 Primary research

    • 1.3.5 Details of primary research

  • 1.4 Information or Data Analysis

    • 1.4.1 Data analysis models

  • 1.5 Market Formulation & Validation

  • 1.6 Model Details

    • 1.6.1 Commodity flow analysis

    • 1.6.2 Volume price analysis

  • 1.7 List of Secondary Sources

  • 1.8 List of Abbreviations

2 Executive Summary

  • 2.1 Market Outlook

  • 2.2 Segment Outlook

3 Market Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook

  • 3.1.1 Parent market outlook

    • 3.1.2 Ancillary market outlook

  • 3.2 Market Segmentation

    • 3.2.1 Analysis

  • 3.3 Market Dynamics

    • 3.3.1 Market driver analysis

    • 3.3.2 Market restraint analysis

    • 3.3.3 Industry opportunities

  • 3.4 Penetration & Growth Prospect Mapping

    • 3.4.1 Penetration & growth prospect mapping analysis

  • 3.5 Business Environment Analysis Tools

    • 3.5.1 Porter's five forces analysis

    • 3.5.2 PESTLE analysis

    • 3.5.3 Major deals & strategic alliances analysis

4 Peripheral Arterial Disease (PAD) Therapeutics Market: Technology Type Analysis

  • 4.1 Peripheral Arterial Disease (PAD) Therapeutics Technology Type Market Share Analysis, 2018 & 2026

  • 4.2 Peripheral Arterial Disease (PAD) Therapeutics Technology Type Market: Segment Dashboard

  • 4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment

    • 4.3.1 Anti-Platelet Drugs

    • 4.3.2 Dual Antiplatelet Therapy Drugs

    • 4.3.3 Others

5 Peripheral Arterial Disease (PAD) Therapeutics Market: Product Analysis

  • 5.1 Peripheral Arterial Disease (PAD) Therapeutics Product Market Share Analysis, 2018 & 2026

  • 5.2 Peripheral Arterial Disease (PAD) Therapeutics Product Market: Segment Dashboard

  • 5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment

6 Peripheral Arterial Disease (PAD) Therapeutics Market: Application Analysis

  • 6.1 Peripheral Arterial Disease (PAD) Therapeutics Application Market Share Analysis, 2018 & 2026

  • 6.2 Peripheral Arterial Disease (PAD) Therapeutics Application Market: Segment Dashboard

  • 6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment

    • 6.3.1 Hospitals

    • 6.3.2 Clinics

    • 6.3.3 Others

7 Peripheral Arterial Disease (PAD) Therapeutics Market: Regional Analysis

  • 7.1 Peripheral Arterial Disease (PAD) Therapeutics Regional Market Share Analysis, 2018 & 2026

  • 7.2 Peripheral Arterial Disease (PAD) Therapeutics Regional Market: Segment Dashboard

  • 7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)

  • 7.4 List of Players at Regional Level

    • 7.4.1 North America

    • 7.4.2 Europe

    • 7.4.3 Asia Pacific

  • 7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)

    • 7.5.1 North America

    • 7.5.2 Europe

    • 7.5.3 Asia Pacific

    • 7.5.4 Latin America

    • 7.5.5 MEA

  • 7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026

    • 7.6.1 North America

    • 7.6.2 Europe

    • 7.6.3 Asia Pacific

    • 7.6.4 Latin America

    • 7.6.5 Middle East & Africa

8 Competitive Analysis

  • 8.1 Recent Developments & Impact Analysis, by Key Market Participants

  • 8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)

  • 8.3 Vendor Landscape

    • 8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)

9 Company Profiles

  • 9.1 Betagenon AB (Sweden)

    • 9.1.1 Betagenon AB (Sweden) Company overview

    • 9.1.2 Financial performance

    • 9.1.3 Product benchmarking

    • 9.1.4 Strategic initiatives

    • 9.1.5 SWOT analysis

  • 9.2 Proteon Therapeutics, Inc. (US)

    • 9.2.1 Proteon Therapeutics, Inc. (US) Company overview

    • 9.2.2 Financial performance

    • 9.2.3 Product benchmarking

    • 9.2.4 Strategic initiatives

    • 9.2.5 SWOT analysis

  • 9.3 Bayer HealthCare Pharmaceuticals (Germany)

    • 9.3.1 Bayer HealthCare Pharmaceuticals (Germany) Company overview

    • 9.3.2 Financial performance

    • 9.3.3 Product benchmarking

    • 9.3.4 Strategic initiatives

    • 9.3.5 SWOT analysis

  • 9.4 miRagen Therapeutics, Inc. (US)

    • 9.4.1 miRagen Therapeutics, Inc. (US) Company overview

    • 9.4.2 Financial performance

    • 9.4.3 Product benchmarking

    • 9.4.4 Strategic initiatives

    • 9.4.5 SWOT analysis

  • 9.5 Multi Gene Vascular Systems Ltd (Israel)

    • 9.5.1 Multi Gene Vascular Systems Ltd (Israel) Company overview

    • 9.5.2 Financial performance

    • 9.5.3 Product benchmarking

    • 9.5.4 Strategic initiatives

    • 9.5.5 SWOT analysis

  • 9.6 Sanofi S.A. (France)

    • 9.6.1 Sanofi S.A. (France) Company overview

    • 9.6.2 Financial performance

    • 9.6.3 Product benchmarking

    • 9.6.4 Strategic initiatives

    • 9.6.5 SWOT analysis

  • 9.7 Merck & Co., Inc. (US)

    • 9.7.1 Merck & Co., Inc. (US) Company overview

    • 9.7.2 Financial performance

    • 9.7.3 Product benchmarking

    • 9.7.4 Strategic initiatives

    • 9.7.5 SWOT analysis

  • 9.8 AnGes MG, Inc. (Japan)

    • 9.8.1 AnGes MG, Inc. (Japan) Company overview

    • 9.8.2 Financial performance

    • 9.8.3 Product benchmarking

    • 9.8.4 Strategic initiatives

    • 9.8.5 SWOT analysis

  • 9.9 AstraZeneca Plc. (UK)

    • 9.9.1 AstraZeneca Plc. (UK) Company overview

    • 9.9.2 Financial performance

    • 9.9.3 Product benchmarking

    • 9.9.4 Strategic initiatives

    • 9.9.5 SWOT analysis

  • 9.10 Symic Bio, Inc. (US)

    • 9.10.1 Symic Bio, Inc. (US) Company overview

    • 9.10.2 Financial performance

    • 9.10.3 Product benchmarking

    • 9.10.4 Strategic initiatives

    • 9.10.5 SWOT analysis

  • 9.11 Athersys, Inc. (US)

    • 9.11.1 Athersys, Inc. (US) Company overview

    • 9.11.2 Financial performance

    • 9.11.3 Product benchmarking

    • 9.11.4 Strategic initiatives

    • 9.11.5 SWOT analysis

  • 9.12 ViroMed Co. Ltd. (Korea)

    • 9.12.1 ViroMed Co. Ltd. (Korea) Company overview

    • 9.12.2 Financial performance

    • 9.12.3 Product benchmarking

    • 9.12.4 Strategic initiatives

    • 9.12.5 SWOT analysis

  • 9.13 Bristol-Myers Squibb Company (US)

    • 9.13.1 Bristol-Myers Squibb Company (US) Company overview

    • 9.13.2 Financial performance

    • 9.13.3 Product benchmarking

    • 9.13.4 Strategic initiatives

    • 9.13.5 SWOT analysis

  • 9.14 TheraVasc Inc. (US)

    • 9.14.1 TheraVasc Inc. (US) Company overview

    • 9.14.2 Financial performance

    • 9.14.3 Product benchmarking

    • 9.14.4 Strategic initiatives

    • 9.14.5 SWOT analysis

 

The List of Tables and Figures (Totals 61 Figures and 144 Tables)

  • Figure Anti-Platelet Drugs Peripheral Arterial Disease (PAD) Therapeutics market, 2015 - 2026 (USD Million)

  • Figure Dual Antiplatelet Therapy Drugs Peripheral Arterial Disease (PAD) Therapeutics market, 2015 - 2026 (USD Million)

  • Figure Others Peripheral Arterial Disease (PAD) Therapeutics market, 2015 - 2026 (USD Million)

  • Figure Hospitals market, 2015 - 2026 (USD Million)

  • Figure Clinics market, 2015 - 2026 (USD Million)

  • Figure Others market, 2015 - 2026 (USD Million)

  • Table List of players in North America

  • Table List of players in Europe

  • Table List of players in Asia Pacific

  • Table SWOT analysis

  • Table North America Peripheral Arterial Disease (PAD) Therapeutics market, by country, 2015 - 2026 (USD Million)

  • Table North America Peripheral Arterial Disease (PAD) Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table North America Peripheral Arterial Disease (PAD) Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table North America Peripheral Arterial Disease (PAD) Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.S. Peripheral Arterial Disease (PAD) Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table U.S. Peripheral Arterial Disease (PAD) Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table U.S. Peripheral Arterial Disease (PAD) Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Canada Peripheral Arterial Disease (PAD) Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table Canada Peripheral Arterial Disease (PAD) Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table Canada Peripheral Arterial Disease (PAD) Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Europe Peripheral Arterial Disease (PAD) Therapeutics market, by country, 2015 - 2026 (USD Million)

  • Table Europe Peripheral Arterial Disease (PAD) Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table Europe Peripheral Arterial Disease (PAD) Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table Europe Peripheral Arterial Disease (PAD) Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.K. Peripheral Arterial Disease (PAD) Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table U.K. Peripheral Arterial Disease (PAD) Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table U.K. Peripheral Arterial Disease (PAD) Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Germany Peripheral Arterial Disease (PAD) Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table Germany Peripheral Arterial Disease (PAD) Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table Germany Peripheral Arterial Disease (PAD) Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table France Peripheral Arterial Disease (PAD) Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table France Peripheral Arterial Disease (PAD) Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table France Peripheral Arterial Disease (PAD) Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Italy Peripheral Arterial Disease (PAD) Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table Italy Peripheral Arterial Disease (PAD) Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table Italy Peripheral Arterial Disease (PAD) Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Spain Peripheral Arterial Disease (PAD) Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table Spain Peripheral Arterial Disease (PAD) Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table Spain Peripheral Arterial Disease (PAD) Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Asia Pacific Peripheral Arterial Disease (PAD) Therapeutics market, by country, 2015 - 2026 (USD Million)

  • Table Asia Pacific Peripheral Arterial Disease (PAD) Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table Asia Pacific Peripheral Arterial Disease (PAD) Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table Asia Pacific Peripheral Arterial Disease (PAD) Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table China Peripheral Arterial Disease (PAD) Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table China Peripheral Arterial Disease (PAD) Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table China Peripheral Arterial Disease (PAD) Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Japan Peripheral Arterial Disease (PAD) Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table Japan Peripheral Arterial Disease (PAD) Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table Japan Peripheral Arterial Disease (PAD) Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table India Peripheral Arterial Disease (PAD) Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table India Peripheral Arterial Disease (PAD) Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table India Peripheral Arterial Disease (PAD) Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Latin America Peripheral Arterial Disease (PAD) Therapeutics market, by country, 2015 - 2026 (USD Million)

  • Table Latin America Peripheral Arterial Disease (PAD) Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table Latin America Peripheral Arterial Disease (PAD) Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table Latin America Peripheral Arterial Disease (PAD) Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Brazil Peripheral Arterial Disease (PAD) Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table Brazil Peripheral Arterial Disease (PAD) Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table Brazil Peripheral Arterial Disease (PAD) Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Mexico Peripheral Arterial Disease (PAD) Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table Mexico Peripheral Arterial Disease (PAD) Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table Mexico Peripheral Arterial Disease (PAD) Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Argentina Peripheral Arterial Disease (PAD) Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table Argentina Peripheral Arterial Disease (PAD) Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table Argentina Peripheral Arterial Disease (PAD) Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table MEA Peripheral Arterial Disease (PAD) Therapeutics market, by country, 2015 - 2026 (USD Million)

  • Table MEA Peripheral Arterial Disease (PAD) Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table MEA Peripheral Arterial Disease (PAD) Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table MEA Peripheral Arterial Disease (PAD) Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table South Africa Peripheral Arterial Disease (PAD) Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table South Africa Peripheral Arterial Disease (PAD) Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table South Africa Peripheral Arterial Disease (PAD) Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Nigeria Peripheral Arterial Disease (PAD) Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table Nigeria Peripheral Arterial Disease (PAD) Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table Nigeria Peripheral Arterial Disease (PAD) Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Company market position analysis

  • Table Company Profiles

  • Table Betagenon AB (Sweden) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Proteon Therapeutics, Inc. (US) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Bayer HealthCare Pharmaceuticals (Germany) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table miRagen Therapeutics, Inc. (US) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Multi Gene Vascular Systems Ltd (Israel) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Sanofi S.A. (France) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Merck & Co., Inc. (US) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table AnGes MG, Inc. (Japan) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table AstraZeneca Plc. (UK) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Symic Bio, Inc. (US) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Athersys, Inc. (US) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table ViroMed Co. Ltd. (Korea) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Bristol-Myers Squibb Company (US) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table TheraVasc Inc. (US) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

Report Purchase

reports
$3850
$7700
BUY NOWClick MeBUY NOW
top